Keywords: XOMA Corp, Perindopril, Amlodipine, Ph III, Blood pressure, Servier
XOMA's perindopril and amlodipine FDC meets primary endpoint in Ph III blood pressure trial
Article | 23 November 2012
California, USA-based XOMA Corp (Nasdaq: XOMA) says the 837-patient Phase III PATH trial (Perindopril Amlodipine for the Treatment of Hypertension) ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- New Zealand declines Alexion's funding application for Solaris
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Elan makes "transformational" acquisitions and a divestment
